Multi-omics research contributes to early screening, diagnosis and treatment of liver cancer.
10.3760/cma.j.cn501113-20220628-00357
- Author:
Wen Cong DAI
1
;
Rong FAN
1
;
Ai Hua SUN
2
;
Fu Chu HE
2
;
Jin Lin HOU
1
Author Information
1. Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangdong Provincial Institute of Liver Diseases, Guangzhou 510515, China.
2. State Key Laboratory of Proteomics, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Hepatocellular/therapy*;
Early Detection of Cancer/methods*;
Hepatitis, Viral, Human;
Humans;
Liver Neoplasms/therapy*;
Prognosis
- From:
Chinese Journal of Hepatology
2022;30(8):793-796
- CountryChina
- Language:Chinese
-
Abstract:
In 2016, the World Health Organization set an ambitious goal of reducing viral hepatitis-related deaths by 65% by 2030. The key to this goal is to reduce viral hepatitis-related HCC deaths. Liver cancer is the fourth most common malignant tumor and the second leading cause of cancer death in China. The onset of HCC is insidious, and most patients are already in the middle and late stage when diagnosed. Despite the great progress on management of HCC, the therapeutic effect and prognosis of HCC are still unsatisfactory. Therefore, multi-dimensional and comprehensive analysis of the mechanism of liver cancer, improving the early screening, diagnosis and treatment rate of liver cancer are the key points of reducing the harm of liver cancer in China. In recent years, multi-omics studies have been widely applied in the field of liver cancer, providing a basis for the pathogenesis of liver cancer, early detection and diagnosis, development of individual treatment strategies and prognosis assessment. This issue will focus on the application of genomics, proteomics, metabolomics and imaging omics in early screening, diagnosis and treatment of liver cancer.
